6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer. However, the optimum duration of treatment has been debated. We did a non-inferiority trial of a shorter exposure of 6 months versus the standard 12 months of tras...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 14; no. 8; pp. 741 - 748
Main Authors:	Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Tubiana-Mathieu, Nicole, Cany, Laurent, Catala, Stéphanie, Khayat, David, Pauporté, Iris, Kramar, Andrew
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.07.2013 Elsevier Limited
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - secondary Breast Neoplasms - surgery Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical trials Disease-Free Survival Drug Administration Schedule Early Detection of Cancer FDA approval Female France Heart Diseases - chemically induced Hematology, Oncology, and Palliative Medicine Humans Hypotheses Infusions, Intravenous Kaplan-Meier Estimate Mastectomy Middle Aged Neoplasm Recurrence, Local Neoplasms, Second Primary Predictive Value of Tests Proportional Hazards Models Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Radiotherapy, Adjuvant Receptor, ErbB-2 - analysis Receptor, ErbB-2 - genetics Software Time Factors Trastuzumab Treatment Outcome Young Adult France
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!